Sentante Endovascular Robotic Platform Receives CE Mark Approval

May 22, 2026—Sentante, a Lithuania-based medical technology company, announced that its flagship endovascular robotic platform has received CE Mark approval.

Nectero EAST System Evaluated for Treating Small- to Medium-Sized AAA

May 20, 2026—Nectero Therapeutics announced the release of 2-year outcomes from the company’s first-in-human (FIH) trial of the investigational Nectero endovascular aneurysm stabilization treatment (EAST) system.

FDA Approves Reduced Shake Time for Medtronic’s Onyx 18 and Onyx 34

May 19, 2026—Medtronic Neurovascular announced that its Onyx Liquid Embolic System (LES), Onyx 18 and Onyx 34, received FDA approval for a shake time of at least 1 minute with the same product performance.

Artivion Completes Acquisition of Endospan

May 19, 2026—Artivion, Inc. announced that it has completed the acquisition of its long-standing partner Endospan Ltd. On May 8, Artivion announced it was exercising its option to acquire Endospan.

Endologix Acquires Pounce Thrombectomy System From Surmodics

May 19, 2026—Endologix announced the acquisition of the Pounce thrombectomy system from Surmodics, expanding the company’s portfolio of peripheral vascular intervention technologies.

Cagent’s Serranator Sonic IVL System Used in FIH Procedures

May 19, 2026—Cagent Vascular, Inc. announced the successful completion of the first-in-human-use (FIH) procedures with the Serranator Sonic intravascular lithotripsy (IVL) system.

Medtronic’s Concerto Versa Detachable Coil Used in First Commercial Procedures

May 14, 2026—Medtronic announced the first procedures were performed using the Concerto Versa coil, indicated for arterial and venous embolization in the peripheral vasculature to help control bleeding or treat vascular disease.

IDE Approved for Pivotal Study of InspireMD’s SwitchGuard Neuro Protection System

May 14, 2026—InspireMD, Inc., developer of the CGuard Prime carotid stent system for the prevention of stroke, announced that the FDA has approved the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS III pivotal study.